Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Published byTodd Townsend Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells."— Presentation transcript:

1 Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden.
Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. (A) Hematoxylin and eosin (H&E) and immunostaining showing the expression of Maraba proteins and cytokeratin-18 in a triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) treated intratumorally with Maraba (n = 2). Scale bars, 200 μm. NV, no virus. (B to D) Quantification of average non-necrotic regions based on H&E staining obtained for the TNBC PDX (B), the luminal B breast cancer PDX (C), or 4T1 tumors (D) (n = 10; Mann-Whitney two-tailed U test, ***P < 0.005). PBS, phosphate-buffered saline. (E and F) Maraba was administered intratumorally to 4T1 tumors before resection, and the spontaneous lung metastases were visualized by histology (E) (n = 6; Mann-Whitney two-tailed U test, **P < 0.01) or India ink perfusion (F) (n = 5 for control and n = 6 for Maraba-treated mice; Mann-Whitney two-tailed U test, *P < 0.05). (G and H) The experiment was repeated in the EMT6 (G; n = 10) and E0771 (H; n = 10) tumor models. Marie-Claude Bourgeois-Daigneault et al., Sci Transl Med 2018;10:eaao1641 Published by AAAS

Download ppt "Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells."

Similar presentations

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,

Development of preclinical models for the guidance of precision medicine. Development of preclinical models for the guidance of precision medicine. A,
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.

Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Similar presentations

Ads by Google